Equity · Healthcare
AKTX
NASDAQAkari Therapeutics (AKTX)
The line runs 7.53 USD on 24 August through 7.11 USD on 19 November, on a scale from 6 to 12. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.32T USD
- EPS, diluted, year to Dec 2025
- 0.00 USD
- 52-week range
- 3.06 USD – 22.21 USD
- Avg volume
- 611.00
as of Nov 19, 2026
Have Akari Therapeutics (AKTX) insiders bought or sold shares recently?
In the 90 days to 21 Nov 2026, no Akari Therapeutics insider bought or sold shares on the open market; all 10 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 21 Nov 2026, newest Form 4 filing 17 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Nov 2026 | Farag Kameel D.Interim CFO | Award | 2,873 | 26K USD |
| 14 Oct 2026 | Patel Sandip IDirector | Option exercise | 10,052 | 4 USD |
| 14 Oct 2026 | Bazemore Robert BDirector | Option exercise | 3,866 | 2 USD |
| 14 Oct 2026 | Gaslightwala AbizerCEO | Option exercise | 27,066 | 11 USD |
| 05 Oct 2026 | Prudo-Chlebosz RaymondDirector | Award | 3,240 | 26K USD |
| 05 Oct 2026 | Huh HoyoungDirector | Award | 6,160 | 49K USD |
| 05 Oct 2026 | Patel Sandip IDirector | Award | 4,313 | 34K USD |
| 05 Oct 2026 | Bazemore Robert BDirector | Award | 4,677 | 37K USD |
| 05 Oct 2026 | Patel Samir RashmikantDirector | Award | 2,236 | 18K USD |
| 29 Sep 2026 | Gaslightwala AbizerCEO | Award | 6,430 | 62K USD |
Which funds hold Akari Therapeutics (AKTX)?
1 of the 45 institutional funds we track reported a Akari Therapeutics position for the quarter ended 30 Sep 2026 — a combined 201K USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | New position | 21,637 | 201K USD |
What has been filed or recorded for Akari Therapeutics (AKTX)?
The filings we hold for Akari Therapeutics, newest first: 12 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,419 shares | 29K USD notional · <0.001% of shares out |
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,238 shares | 30K USD notional · <0.001% of shares out |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,931 shares | 25K USD notional · <0.001% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 24 shares | 198 USD notional · <0.001% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,624 shares | 14K USD notional · <0.001% of shares out |
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,295 shares | 21K USD notional · <0.001% of shares out |
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 167 shares | 2K USD notional · <0.001% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,197 shares | 10K USD notional · <0.001% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,846 shares | 33K USD notional · <0.001% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,582 shares | 19K USD notional · <0.001% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,394 shares | 11K USD notional · <0.001% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 4,909 shares | 42K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.00 USD | |
| 30 Sep 2026 | Financials | Total assets | 36.6M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 17.5M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.00 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.00 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.00 USD | |
| 31 Dec 2025 | Financials | Net income | −17.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.00 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.00 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.00 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.00 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 0.00 USD |
What do people ask about Akari Therapeutics (AKTX)?
What did Akari Therapeutics shares close at?7.11
Akari Therapeutics closed at 7.11 USD on 19 Nov 2026, down 0.84% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Akari Therapeutics’ market cap?1.32T
Akari Therapeutics is worth 1.32T USD by market value as of 19 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have Akari Therapeutics insiders bought or sold shares recently?10 filings
In the 90 days to 21 Nov 2026, no Akari Therapeutics insider bought or sold shares on the open market; all 10 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Akari Therapeutics?1 of 45
1 of the 45 funds we track reported a Akari Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Citadel Advisors. See Funds
When did Akari Therapeutics last report earnings?0.00
Akari Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.00 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words